Kura Oncology (KUR) Stock Statistics & Valuation Metrics

Kura Oncology has a market cap or net worth of €671.00M. The enterprise value is €629.23M.

Kura Oncology has 88,329,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kura Oncology’s return on equity (ROE) is -1.60 and return on invested capital (ROIC) is -48.76%.

The current PE Ratio of Kura Oncology is ―. Kura Oncology’s PEG ratio is -0.06.

In the last 12 months, Kura Oncology had revenue of 67.48M and earned -278.67M in profits. Earnings per share was -3.18.

In the last 12 months, operating cash flow was -64.06M and capital expenditures -6.64M, giving a free cash flow of -70.70M billion.

Kura Oncology pays an annual dividend of ―, resulting in a dividend yield of ―

Kura Oncology upcoming earnings date is Apr 30, 2026, After Close (Confirmed).

Kura Oncology as a current ratio of 6.06, with Debt / Equity ratio of 11.75%

In the past 12 months, Kura Oncology has paid 297.00K in taxes.

Kura Oncology EV to EBITDA ratio is -2.58, with an EV/FCF ratio of -11.07.

Kura Oncology has €667.24M in cash and marketable securities with €20.46M in debt, giving a net cash position of €646.78M billion.

Gross margin is 94.56%, with operating margin of -449.94%, and net profit margin of -412.95%.

The average price target for Kura Oncology is €24.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy